TY - JOUR T1 - Prognostic Role of <em>BRAF</em> Mutations in Colorectal Cancer Liver Metastases JF - Anticancer Research JO - Anticancer Res SP - 4805 LP - 4811 VL - 36 IS - 9 AU - EMMANOUIL PIKOULIS AU - GEORGIOS A. MARGONIS AU - NIKOLAOS ANDREATOS AU - KAZUNARI SASAKI AU - ANASTASIOS ANGELOU AU - GEORGIOS POLYCHRONIDIS AU - ANASTASIA PIKOULI AU - ELENA RIZA AU - TIMOTHY M. PAWLIK AU - EFSTATHIOS ANTONIOU Y1 - 2016/09/01 UR - http://ar.iiarjournals.org/content/36/9/4805.abstract N2 - Background/Aims: The impact of tumor biology on prognosis in patients with colorectal liver metastasis (CRLM) has been the topic of intense research. Specifically, the presence of BRAF mutations has been recently associated with adverse long-term outcomes. We examined the existing literature on the prognostic implications of BRAF mutations in patients with CRLM. Materials and Methods: A structured review of the literature was performed between 5/1/2016 and 6/1/2016 using the PubMed database. Original research articles published between 1/1/2010 and 4/01/2016 were considered eligible. The primary end-points were overall survival (OS)/disease-specific survival (DSS) and recurrence-free survival (RFS) among patients with BRAF mutated CRLM who underwent resection. Results: Eight studies were included. All studies reported on OS/DSS, while 6 reported on RFS. BRAF mutant status was a strong independent predictor of both worse OS/DSS and RFS in 7 and 4 studies, respectively. Conclusion: BRAF-mutant lesions are consistently associated with poor prognosis. Consequently, the indications of CRLM resection in this patient group should be reconsidered. ER -